Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 4/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28654934 | 0.84 | LPL (0.33) | LPLLIPGP2RX7MAPK1 | |
| SCHEMBL20865722 | 0.82 | MEN1 (0.33) | LPLLIPGP2RX7MAPK1 | |
| SCHEMBL28630852 | 0.82 | AR (0.32) | LPLLIPG | |
| SCHEMBL27157750 | 0.81 | ROCK1 (0.36) | LPLLIPGROCK1 | |
| SCHEMBL21493489 | 0.80 | KIF11 (0.39) | LPLLIPGROCK1P2RX7 | |
| SCHEMBL28660659 | 0.80 | CSF1R (0.33) | LPLLIPGP2RX7 | |
| SCHEMBL19098449 | 0.80 | ESR2 (0.32) | LPLLIPGP2RX7 | |
| SCHEMBL28658657 | 0.80 | LPL (0.35) | LPLLIPGROCK1P2RX7 | |
| SCHEMBL15288616 | 0.75 | LIPG (0.40) | LPLLIPGROCK1 | |
| SCHEMBL22357671 | 0.73 | ROCK1 (0.37) | LPLLIPGROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3702354-B1 | COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF | HAIHE BIOPHARMA CO LTD (CN) | 2024-05-22 | — | — | EP | disclosed |
| US-11465984-B2 | Compound having ERK kinase inhibitory activity and use thereof | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) | 2022-10-11 | — | — | US | disclosed |
| EP-3702354-A1 | COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF | Shanghai Haihe Pharmaceutical Co., Ltd. (CN) | 2020-09-02 | — | — | EP | disclosed |
| EP-3702354-A1 | COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF | Shanghai Haihe Pharmaceutical Co., Ltd. (CN) | 2020-09-02 | — | — | EP | disclosed |
| US-20200247781-A1 | COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF | HAIHE BIOPHARMA CO., LTD. (CN) | 2020-08-06 | — | — | US | disclosed |
| US-20200247781-A1 | COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF | HAIHE BIOPHARMA CO., LTD. (CN) | 2020-08-06 | — | — | US | disclosed |
| WO-2019062949-A1 | COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF | 上海海和药物研究开发有限公司 | 2019-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11465984-B2 | Compound having ERK kinase inhibitory activity and use thereof | MAPK1, MAPK4, MAPK7 | LPL 4234/4885LIPG 2409/4885ROCK1 405/4885 |
| US-20200247781-A1 | COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF | MAPK1, MAPK4, MAPK7 | LPL 4234/4885LIPG 2409/4885ROCK1 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.